Advancing scientific knowledge

Our Science

Advancing antibody drug conjugates with a novel class of PBD dimersADC Therapeutics’ proprietary ADCs are highly targeted drug constructs that combine monoclonal antibodies specific to surface tumor targets with a novel class of highly potent PBD-dimer toxins.PBD dimers do not distort the DNA structure, which makes them invisible to repair mechanisms and allows the cross-links to persist within the DNA.
Unlike earlier generation PBD chemistry, ADC Therapeutics’ proprietary PBD dimers are not a substrate for multi-drug resistance proteins—even in hard-to-treat tumors.Our PBD-dimer technology: A novel approach to hematologic cancers and solid tumors

• 1The antibody drug conjugate (ADC) binds to a specific tumor cell surface antigen and is internalized^1,2
• 2The potent pyrrolobenzodiazepine (PBD) dimer toxin is released inside the cell, where it then creates a covalent cross-link between the strands of the DNA double helix^2,3
• 3Because these cross-links do not distort the DNA structure, it is hypothesized that they remain invisible to repair mechanisms and can covertly persist to interrupt cell division and cause tumor cell death^1-3

Watch an MOA video about our first approved ADC, loncastuximab tesirine-lpyl (2:32)